Seres Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview

Seres Therapeutics

29/10/2024 13:48

* Seres Therapeutics Inc  MCRB.OQ   MCRB.O  is expected
to show a
fall in quarterly revenue when it reports  results on October 31
(estimated) for the period ending September 30 2024
    * 
    * ​LSEG's mean analyst estimate for Seres Therapeutics Inc
is for
a loss of 25 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 0.6%
in the last three months. ​
    * Wall Street's median 12-month price target for Seres
Therapeutics Inc is $1.25​, above​ its last closing price
of $0.70. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.27       -0.27      -0.22     Beat    19.7
 Mar. 31 2024  -0.35       -0.34      -0.27     Beat    20.8
 Dec. 31 2023  -0.40       -0.50      -0.32     Beat    35.6​
 Sep. 30 2023  -0.49       -0.50      -0.37     Beat    26.2
 ​​Jun.        0.53        0.53       0.36      Missed  -32.6
 30 2023                                                
 Mar. 31 2023  -0.56       -0.55      -0.57     Missed  -3.8​
 Dec. 31 2022  -0.30       -0.46      -0.54     Missed  -16.1
 Sep. 30 2022  -0.50       -0.47      -0.49     Missed  -4.5
 This summary was machine generated October 29 at 13:48 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)